# case_26_node_2

## Outcome

- Run status: complete; final source: LLM.
- Target: osimertinib monotherapy after afatinib failure in EGFR S768I lung adenocarcinoma with T790M-positive lung and CNS progression.
- The final answer predicted limited benefit/stability with low confidence, no citations, and mild expected toxicity.

## Component audit

- Query/plan correctly focused on T790M, CNS penetration, sequencing after afatinib and early response/safety.
- Retrieval still admitted nine items as analog/partial support; five were low relevance and one had a different target entity. The context contained no direct findings and retained three weak findings, none cited by Generate.
- AnswerMemory remained atomic: no merged claims. This confirms the newer memory fix is holding in this case.
- Runtime was 964.0 seconds; 10 rerank calls consumed 580.1 seconds and four Evidence Review calls consumed 266.3 seconds. Increasing the output ceiling did not by itself guarantee fewer rerank attempts; actual per-call statuses must be measured before claiming an improvement.

## Classification

- General issue: the applicability gate is still needed even when the query is clinically specific; retrieval similarity alone admits unrelated EGFR cases and treatment regimens.
- Positive behavior: the final answer did not cite or present the weak analogs as direct evidence and preserved low confidence.
- Performance follow-up: inspect the ten rerank call statuses and candidate batch sizes; separate logical batches from retries before changing the schema again.
